Trial Profile
A Phase 3 Multicenter, Randomized, Double-Blind and Placebo-Controlled Study, and Open Study of KW-0761 in Patients With HTLV-1 Associated Myelopathy (HAM)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 15 Apr 2022
Price :
$35
*
At a glance
- Drugs Mogamulizumab (Primary)
- Indications Spinal cord disorders
- Focus Therapeutic Use
- Sponsors Kyowa Kirin
- 07 Apr 2022 Status changed from completed to discontinued.
- 31 Aug 2021 Status changed from active, no longer recruiting to completed.
- 06 Nov 2020 Planned End Date changed from 1 Dec 2020 to 1 Jun 2021.